Status:
RECRUITING
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
Lead Sponsor:
American University
Collaborating Sponsors:
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Conditions:
Autism
Autism Spectrum Disorder
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
The goal of this study is to determine the impact of neuromodulation to the cerebellum on social and executive functions in neurotypical young adults and young adults with autism.
Detailed Description
Autism spectrum disorder is a prevalent neurodevelopmental condition characterized by deficits in social communication and the presence of repetitive and inflexible behaviors. There are currently few ...
Eligibility Criteria
Inclusion
- Please note: This study takes place at American University and Georgetown University in Washington, DC. We do not have funds for travel and lodging available for this study, so participants should be local to the DC region.
- All participants
- Aged 18-35
- Able to provide written, informed consent
- NIH Toolbox age-adjusted Cognitive Function Composite standard score ≥ 85
- Native English speaker
- Right-handed
- Not pregnant
- Able to attend all study sessions
- Pass safety screening for MRI and neuromodulation (e.g. no metal in body, implanted devices, history of seizure, claustrophobia)
- Additional INCLUSION criteria for adults with autism Either
- Prior research-reliable diagnosis of autism spectrum disorder (ASD) Or
- Meet DSM-5 criteria for ASD confirmed with ADOS-2 via research-reliable clinical assessment
Exclusion
- Neurotypical adults
- Age \<18 or \>35
- NIH Toolbox age-adjusted Cognitive Function Composite standard score \< 85
- Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia)
- Current or prior history of neurological or neurodevelopmental condition or brain injury
- Psychotropic medication
- Pregnancy
- Adults with autism
- Age \<18 or \>35
- Participants with a legal authorized representative
- NIH Toolbox age-adjusted Cognitive Function Composite standard score \< 85
- Contraindications for MRI or neuromodulation with tDCS (e.g. metal in body, pacemaker or other implanted device, history of seizure, claustrophobia)
- Pregnancy
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05396352
Start Date
January 1 2022
End Date
December 31 2025
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
American University
Washington D.C., District of Columbia, United States, 20016